Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

vortioxetine

- PMLiVE

EMA offers orphan drug benefits for Ebola research

Incentives to encourage development of new treatments for the virus

EMA expands adverse event reporting website

Opens it up to all nationally-authorised medicines

- PMLiVE

EMA safety panel rules no change needed for Ariad’s Iclusig

Positive news comes after blood clot concerns

- PMLiVE

EMA draws fire on new clinical reports policy

Has recently come under pressure from transparency groups

- PMLiVE

NICE recommends Lundbeck’s alcohol dependency drug

NHS patients to have access to Selincro to help control drinking

- PMLiVE

EMA to review experimental Ebola drugs

Response comes as death-toll tops 3,000

- PMLiVE

EMA wants to embed patient viewpoint within drug assessment

Will pilot CHMP benefit-risk evaluation project

Gilead Sciences

Gilead’s hep C combination Harvoni recommended for EU approval

CHMP backs combination of Sovaldi and ledipasvir

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Lundbeck launches Brintellix in first EU market

The antidepressant set to sell worldwide

- PMLiVE

Drug regulators collaborate to tackle Ebola outbreak

EMA and FDA team up with global partners to accelerate access to medicines

- PMLiVE

Amgen submits melanoma and cholesterol drugs to EMA

Regulator will assess talimogene laherparepvec and evolocumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links